ネシリチドは,慢性心不全の患者および血清クレアチニンの悪化で腎機能を改善しません
David J Wang1, Thomas C Dowling, Dean Meadows
1Department of Medicine, University of Maryland School of Medicine, and Baltimore Veterans Administration Medical Center, USA.
Circulation
|September 1, 2004
まとめ
ネシリチドは,心臓機能不全や腎不全が悪化している患者の腎機能を改善しませんでした. ネシリチドに影響を与える要因を理解するためにさらなる研究が必要です.
科学分野:
- 心臓病学 心臓病学
- ネフロロジーはネフロロジーを用います.
- 薬理学 薬理学とは
背景:
- 合成脳ナトリウレチンペプチドであるネシリチドは,症状性心不全の治療に承認されています.
- 前回のネシリチドが心不全患者の腎臓に及ぼす影響に関する研究では,GFR,腎臓の血流量,ナトリウレシス,および二尿症に関して矛盾する結果が得られた.
研究 の 目的:
- 腎機能障害のリスクが高い患者の腎機能に対するネシリチドの影響を評価する.
- ネシリチドのグルメルフィルタレーション率 (GFR),腎臓のプラズマフロー,尿中のナトリウム分泌,尿出荷に対する効果を評価する.
主な方法:
- クレアチニン濃度が上昇した15人の患者を対象とした,ダブルブラインド,プラセボ対照,クロスオーバー研究です.
- 患者はネシリタイドまたはプラセボを24時間連続して受けた.
- 腎機能は,GFRに対するイオタラマートクリアランスと,腎血流に対するパラアミノヒププラートクリアランスを用いて評価された.
主要な成果:
- ネシリチド治療とプラセボ治療の日間のGFR,効果的な腎血流量,尿出力,またはナトリウム排出の有意な違いは観察されなかった.
- 24時間の平均尿出量は,プラセボで113mL/h,ネシリタイドで110mL/hでした.
- プラセボ治療とネシリチド治療の両方において,平均GFRは40.9mL/minであった.
結論:
- ネシリチドは,不補償性心不全および軽度の慢性腎不全患者の腎機能の改善を示さなかった.
- ネシリチドの有効性を制限する潜在的な要因には,腎不全,血液動力学的変化,ナトリウムバランス,心不全の重症度,薬剤投与量が含まれます.
- これらの要因のさらなる理解は,ネシリチドの臨床応用を最適化するために極めて重要です.
関連する概念動画
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...